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The introduction in 1991 of a tyrosinase-specific reverse transcrip-
tion polymerase chain reaction (RT-PCR) which can sensitively
detect occult melanoma cells in peripheral blood (Smith et al,
1991), has created perspectives to carefully monitor dissemination
of melanoma cells. The clinical relevance of this detection method
has been demonstrated by various groups. Shorter survival is
observed in patients with a positive tyrosinase PCR outcome
(Kunter et al, 1996; Mellado et al, 1996) and semi-quantitative
tyrosinase PCR results correlate with response to treatment
(Brossart et al, 1995).
Although it was originally reported that tyrosinase mRNA could
be detected in all patients with distant metastases (Brossart et al,
1993), various groups could not reproduce this high sensitivity of
detection (reviewed in Keilholz et al, 1997). The use of multiple
melanoma-specific markers increases the sensitivity of detection
(Hoon et al, 1995; Curry, 1998). We recently described that a
nested PCR for the melanoma antigen MART-1 (melanoma
antigen recognized by T-cells) is more sensitive than the widely-
used tyrosinase PCR (De Vries et al, 1999), although others have
previously described that tyrosinase PCR is more sensitive than
MART-1 PCR (Curry et al, 1998). In our study, both tyrosinase
and MART-1 PCR were extremely specific: no amplification was
found in non-melanoma blood samples even after 90 cycles of
PCR (60 first PCR, and 30 nested PCR) (De Vries et al, 1999).
Other melanoma antigens such as gp100, Muc-18 and p97 were
less specific, since the mRNAs of these antigens were detected by
PCR in blood of normal volunteers (Brouwenstijn et al, 1997;
Curry et al, 1998). Similarly, Burchill and co-workers found
expression of cytokeratins 8 and 19 in peripheral blood (Burchill
et al, 1995), excluding these cytokeratins as markers for circu-
lating carcinoma cells.
In the present study, we tested the value of a specific RT-PCR
for melanoma inhibitory activity (MIA) in the detection of
melanoma cells in peripheral blood. MIA has been described as a
gene which was widely expressed in melanoma cell lines and not
expressed in peripheral blood, as investigated by Northern blotting
(Blesch et al, 1994). Interestingly, glioma cells also expressed
MIA, raising the possibility that MIA is more generally expressed
in neuroectodermal tissues (Blesch et al, 1994). Also, after 25
cycles of RT-PCR, MIA could not be detected in a wide variety of
non-melanoma cell lines, but it was detected at low levels in skin
biopsies and at high levels in primary melanoma and melanoma
metastasis lesions (Bosserhoff et al, 1996).
This reported melanocyte- and/or neuroectodermal specificity
of MIA and the parallel with tyrosinase (Wimmer et al, 1997) that
the MIA protein is present in serum of melanoma patients at
increased levels with disease (Bosserhoff et al, 1997), prompted us
to investigate whether a MIA-specific RT-PCR can be used for the
detection of melanoma cells in the circulation. A pilot study
promisingly showed that MIA PCR is suitable and more sensitive
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widely used tyrosinase PCR (La Valle et al, 1998). We investigated
the presence of MIA mRNA in 19 human melanoma cell lines,
16 non-melanoma cell lines, 14 blood samples from melanoma
patients, in six blood samples from non-melanoma cancer patients
and in seven blood samples from healthy volunteers.
MATERIALS AND METHODS
Cell lines
Nineteen human melanoma cell lines and 16 non-melanoma cell
lines were used in this study, most of these cell lines were
described previously (De Vries et al, 1997). The melanoma cell
lines were: BLM, MV3, MV1, MEL57, M14, 1F6, 1F6-m, 530,
SK-MEL-28, A375P, A375M, Omel2, Bowes, MD3A, M24met,
E10, 518A2, 603 and MZ2-MEL-3.0. The 16 non-melanoma cell
lines were mainly tumour cell lines, all of them of various histo-
logical origin. These were: UMSCC2 (head-and-neck squamous
cell carcinoma), CaCo2 (colorectal carcinoma), HEL
(erythroleukemia), LB23 (sarcoma), LB37 (non-squamous cell
lung carcinoma), HaCaT (immortalized keratinocytes), BB49
(head-and-neck cancer), A431 (cervical carcinoma), HFF (human
foreskin fibroblasts), Jurkat (T-cell leukaemia), U937 (histiocytic
lymphoma), Daudi (Burkitt’s lymphoma), HT29 (colon adeno-
carcinoma), K562 (chronic myelogeneous leukaemia), HT1080
(fibrosarcoma) and MOLT-4 (acute lymphoblastic leukaemia).
Suppliers of cell lines are mentioned elsewhere (De Vries et al,
1997), all other cell lines were from the American Type Culture
Collection (Rockville, MD, USA). Cultured foreskin-derived
melanocytes were also analysed.
Blood samples
Blood samples were collected from seven healthy volunteers, six
cancer patients without melanoma (two adenocarcarcinoma of the
kidney, one adenocarcinoma of the pancreas, one small cell lung
carcinoma, one testis carcinoma, one head-and-neck squamous
cell carcinoma), seven melanoma patients who were previously
tested negative for tyrosinase and MART-1 and seven melanoma
patients who were previously tested positive for tyrosinase and
MART-1 (De Vries et al, 1999).
RNA isolation
To avoid contamination, separate rooms were used for RNA isola-
tion, PCR, PCR analysis and sequencing. A one-way route and
different laboratory clothing for each room was used, thus PCR
product could not enter the RNA isolation laboratory. RNA
isolation procedure from blood and from cell lines was described
previously (De Vries et al, 1997, 1999).
Reverse transcription
Reverse transcription was performed as described previously
(De Vries et al, 1997, 1999). Briefly, 2 mg of total RNA was used
for reverse transcription in 20 ml and supplied with 80 ml distilled
water. From this mixture, 5 ml was used for each PCR, equal to 100
ng reverse transcribed RNA, hereby avoiding inaccurate pipetting
of small volumes.
PCR
The primers used in this study are listed in Table 1. Specific
primers for phorbobilinogen deaminase (PBGD) and primers
designated MIA1 and MIA2 were designed with the Primer
Express software, version 1.0 (Perkin Elmer Applied Biosystems,
Foster City, CA, USA). When designing these primers, melting
temperatures of the primers were chosen between 58 and 60°C.
MIA3 and MIA4 were suggested by others (La Valle et al, 1998).
Both MIA primer combinations used in the PCR span the large
1 kb intron, both antisense primers MIA2 and MIA4 have
sequences on both exon 3 and exon 4 (Figure 1).
PCR was performed as described (De Vries et al, 1997, 1999),
optimal magnesium chloride concentration at 1.5 PBGD was
amplified for 35 cycles of 0.5 min 94°C followed by 1.5 min at
60°C, MIA was amplified either with primer pairs MIA1 and
MIA2 or with primer pairs MIA3 and MIA4, for 30 cycles and for
60 cycles at the same temperature and time scheme as PBGD.
After each PCR, a final extension was performed for 3 min at
72°C.
Sequence analysis
All three major PCR-bands were cut out of low-melting agarose
and purified using Magic™ DNA clean-up kit (Promega,
Madison, WI, USA) following the manufacturer’s instructions.
Subsequently, the PCR products were sequenced both in the 3¢ and
in the 5¢ direction of the PCR product. During the labelling
reaction, fluorescent dNTPs were incorporated, using the DNA
sequencing kit (Perkin-Elmer Applied Biosystems, Warrington,
UK). Fluorescent sequencing products were separated on a 6%
polyacrylamide gel and analysed on an ABI PRISM 373 (Perkin-
Elmer Applied Biosystems, Warrington, UK). Homology of the
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Table 1 Primer sequences.
Target Primers Sequencea s/asb Product
size
PBGD PBGD-5¢ 5¢-CTGGTAACGGCAATGCGGCT-3¢ s 339 bp
PBGD-3¢ 5¢-GCAGATGGCTCCGATGGTGA-3¢ a
MIA MIA1 5¢-CCAAGTGGTGTATGTCTTCTCCAA-3¢ s 191 bp
MIA2 5¢-GGCAGTAGAAATCCCATTTGTCTGT-3¢ a
MIA MIA3 5¢-TTGCTGTCTGCCTTCTCCG-3¢ s 355 bp
MIA4 5¢-GGCAGTAGAAATCCCATTTGTC-3¢ a
aFrom published sequences; bs = sense primer, as = antisense primer.sequences was analysed using pairwise alignment software
(internetpage: http://dot.imgen.bcm.tcm.edu:9331/).
RESULTS
MIA mRNA in melanoma and non-melanoma cell lines
We first investigated the presence of MIA mRNA in melanoma
and non-melanoma cell lines with 30 and 60 cycles of RT-PCR,
independently with primer set MIA1 and MIA2 and with primer
set MIA3 and MIA4. The results of a selection of these cell lines is
displayed in Figure 2, the overall results are shown in Table 2.
No genomic DNA was amplified with the primers used (results not
shown).
From Figure 2 it is clear that the two sets of primers confirm
each other. The majority of melanoma cell lines showed strong
amplification of MIA after 30 cycles, with the exception of BLM,
MV3 and E10. As reported previously (Bosserhoff et al, 1996),
moderate amplification of MIA mRNA was observed in cultured
melanocytes after 30 cycles of PCR. In the non-melanoma cell
lines, strong MIA PCR signals after 30 cycles of amplification
were observed for only two cell lines: HT29 and HT1080
(Figure 2). A slight MIA band was observed on ethidium bromide-
stained gels in an additional five out of 16 non-melanoma cell
lines (Jurkat, Daudi, K562, MOLT-4, U937) after 30 cycles of
amplification. MIA was detected in all cell lines after 60 cycles of
PCR amplification (Figure 2 and Table 2).
MIA mRNA in blood of melanoma patients and of
non-melanoma patients
Since it was reasoned that MIA could be a specific marker to
detect melanoma cells in the peripheral blood with higher sensi-
tivity and specificity than the thus far used tyrosinase PCR
(La Valle et al, 1998), we performed 30 and 60 cycles of MIA PCR
on blood samples of melanoma patients from a related study
(De Vries et al, 1999).
We selected seven cDNA samples from melanoma patients who
were previously consistently positive for MART-1 and compared
the result with cDNA from seven blood samples from melanoma
1068 TJ de Vries et al
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Table 2 Presence of MIA transcripts as detected by 30 and 60 cycles of
PCR with two MIA-specific primer sets
Samples MIA1,2 MIA1,2 MIA3,4 MIA3,4
30 cycles 60 cycles 30 cycles 60 cycles
Cell cultures and cell lines
Melanocytes 1/1 1/1 1/1 1/1
Melanoma cell lines 16/19 19/19 16/19 19/19
Non-melanoma cell lines 7/16 16/16 7/16 16/16
Blood samples
Blood healthy volunteers 0/7 7/7 0/7 6/7
Blood non-melanoma
cancer patients 0/6 5/6 0/6 5/6
Blood melanoma patients,
tyrosinase and MART-1 – 0/7 7/7 0/7 7/7
Blood melanoma patients,
tyrosinase and MART-1 + 0/7 7/7 0/7 6/7
Genomic DNA
MIA 3
EXON 1 EXON 2 EXON 3
MIA 4
MIA 2
EXON 4
MIA 4
MIA 2
cDNA
EXON 1 EXON 2 EXON 3 EXON 4
191 bp
355 bp
MIA 1
Figure 1 Schematic representation of the primer pairs used for RT-PCR to detect MIA mRNA. Solid boxes represent exons. MIA2 and MIA4 are intron
spanning primersMIA mRNA in (non-)melanoma cells 1069
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patients who were consistently negative for both tyrosinase and
MART-1. Thirteen negative control blood samples, six from non-
melanoma tumour-bearing patients with no history of primary
melanoma and seven from healthy volunteers, were also tested for
MIA mRNA. MIA mRNA was not detected in any blood sample
after 30 cycles of PCR (not shown), nor in the melanoma samples,
or in any of the control blood samples (Table 2). After 60 cycles of
PCR, however, MIA was amplified in almost all blood samples
(Figure 3, Table 2).
When the MIA primers were used in nested fashion (first PCR:
MIA3 and MIA4, nested PCR: MIA1 and MIA2), the same results
were obtained as with 60 cycles MIA3, MIA4 or MIA1, MIA2:
MIA mRNA could be detected in all non-melanoma cell lines and
peripheral blood samples tested (results not shown).
Sequence analysis
The PCR products of 191 and 355 basepairs obtained by using
primer pairs MIA1, MIA2 and MIA3, MIA4 respectively were
analysed by sequence analysis. These PCR products were identical
to the expected MIA cDNA sequence. Occasionally, an extra band
of approximately 170 bp was observed with the primer pair MIA3
and MIA4, for example in Figure 3, lane M3. The subsequent
sequence was identical to the 3¢ part of the PCR product obtained
by MIA3 and MIA4. Upon close analysis, the MIA3 primer
showed high homology (82.4%, with only three mismatches and
100% identity in seven bases at the most 3¢ region, neccesary for
extention) with an internal MIA sequence, thus explaining the
additional PCR-product.
DISCUSSION
In the present study, we investigated whether a MIA-specific PCR
can be added to the list of melanocyte-lineage-specific markers
like tyrosinase and MART-1. To the best of our knowledge, tyrosi-
nase and MART-1 are the only reliable markers for the detection of
melanoma cells in blood (Hoon et al, 1995; Curry et al, 1998;;
De Vries et al, 1999). Apart from melanocyte-lineage markers,
specific tumour cell detection in peripheral blood with a PCR for
the tumour-specific marker MAGE-3 has been reported for
melanoma (Hoon et al, 1995) and in peripheral blood from patients
with malignant tumours of diverse histology (Mori et al, 1997).
Although MIA expression was reported to be specific for
melanoma cells and cells of neuroectodermal origin (Blesch et al,
1994; Bosserhoff et al, 1996), a large panel of melanoma versus
non-melanoma cell lines was never compared. In our panel of 19
melanoma cell lines, we show that 16 out of 19 cell lines were
positive for MIA after 30 cycles of PCR. Besides this, two out of
16 non-melanoma cell lines were positive at a similar level as the
melanoma cell lines, and another five out of 16 cell lines showed
faint expression of MIA. Discrepancies with an earlier report,
where eight out of eight human non-melanoma cell lines did not
show presence of MIA mRNA after 25 cycles of PCR (Bosserhoff
et al, 1996), could be due to the additional five cycles used in our
study and the difference in choice of non-melanoma cell lines. We
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Figure 3 Amplification of MIA in blood of healthy volunteers and melanoma
patients. cDNA from blood of three healthy donors (C1–C3) and melanoma
patients (M1–M7) was amplified with two MIA primer sets. M1–M4 were
positive for melanoma marker MART-1, M5–M7 were negative for MART-1.
As a test for amplifiability, the low copy housekeeping gene PBGD was
amplified (upper panel) and MIA was visualized after 60 cycles of PCR with
primer pairs MIA1 and MIA2 (second panel) and with primer pairs MIA3 and
MIA4 (third panel). After 60 cycles of PCR, MIA was detectable in all blood
samples analysed
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Figure 2 Amplification of MIA in melanoma and in non-melanoma cell lines.
cDNA of non-melanoma cell lines (to the left of the 100 bp marker) and
melanocyte culture and melanoma cell lines (to the right of the 100 bp
marker) was amplified with two MIA primer sets. As a test for amplifiability,
the low copy housekeeping gene PBGD was amplified (upper panel) and
MIA was detected with primer pairs MIA1 and MIA2 for 30 cycles (second
panel) and 60 cycles (third panel) and with primer pairs MIA3 and MIA4 also
for 30 cycles (fourth panel) and 60 cycles (fifth panel). Note that MIA was
detected in most of the melanoma cell lines and in a few non-melanoma cell
lines after 30 cycles and in all cell lines after 60 cycles of PCR1070 TJ de Vries et al
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confirmed our results with two sets of MIA primers. Though we
found MIA mRNA in melanocytes, a previous study denies this
presence in melanocytes (Bosserhoff et al, 1996). An explanation
may be that the melanocytes used in our study were cultured in the
presence of PMA, which has been described as a stimulator for
MIA expression (Bosserhoff et al, 1996). It was reported that MIA
expression inversely correlates with pigmentation in melanoma
metastases (Van Groningen et al, 1995). We previously described
the expression of melanocyte differentiation genes gp100, tyrosi-
nase and MART-1 in the same panel of cell lines as used in this
study (De Vries et al, 1997). We cannot confirm the apparent
inverse correlation in lesions with cell lines: the MIA-negative
melanoma cell lines BLM, MV3 and E10 did not express any of
the pigmentation genes. Other obvious correlations with pigmenta-
tion genes and MIA expression fail to attract our attention:
melanoma cell lines Bowes, MD3A and M24met express MIA but
none of the pigmentation genes (De Vries et al, 1997). Promising
results were obtained with immunochemical determinations of
MIA in serum or plasma from melanoma patients, where the detec-
tion of MIA was more sensitive than detection of S100 protein
(Bosserhoff et al, 1997). At the mRNA level, however, our study
clearly shows that MIA mRNA can be detected in any cell type,
including peripheral blood cells when using enough PCR cycles.
The MIA gene can be listed as one of many ‘illegitimately tran-
scribed’ genes, where illegitimate transcription is defined as tran-
scription of a gene in any cell type (Chelly et al, 1989), which was
previously reported for melanoma antigens gp100 (Keilholz, 1996;
Brouwenstijn et al, 1997; Curry et al, 1998), MUC18 (Curry et al,
1998) and p97 (Curry et al, 1998). Thus, our results do not prove
that a MIA RT-PCR is of value in the detection of minute tumour
load of melanoma cells in the peripheral blood or in the target
organs of the metastatic process.
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